Patent · US Active

Rabies vaccine

US10682426B2 · kind B2 · utility

23Cited by

0References

17Claims

0Family size

Assignee

CureVac AG · DE

Inventors

Margit SCHNEE · Konstanz, DE
Thomas Kramps · Bellinzona, CH
Lothar Stitz · Rottenburg am Neckar, DE
Benjamin PETSCH · Tübingen, DE

Key dates

Filing date	Feb 19, 2016
Grant date	Jun 16, 2020
Priority date	—
Expiry date	Nov 1, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2760/20134
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof.Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Rabies virus infections. The present invention further describes a method of treatment or prophylaxis of rabies using the mRNA sequence.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.